Proteomics International Laboratories Ltd (ASX: PIQ) - Early Detection of Diabetic Kidney Disease - Commercialisation of Diagnostic Kit
Independent Investment Research
Independent Investment Research
PIQ is a biological research and drug discovery company working on the development of simple diagnostic tests for common diseases and the discovery of new therapeutic drugs to treat pain and infection. The breakthrough diagnostic test has the potential to provide the company with significant upside value if the partners for the distribution of the diagnostic test in significant markets can be found. PromarkerD is the first diagnostic test developed that can predict the prevalence of kidney disease in someone with diabetes. This test has the potential to reduce the occurrence of kidney failure in diabetics and reduce the billions of dollars spent on the treatment of chronic kidney disease worldwide. The ingredients for the diagnostic test kits will be manufactured in Melbourne and assembled in Puerto Rico, a US territory and therefore will fall under the umbrella of the US FDA guidelines providing a pathway into the US market. We have assigned PIQ a valuation of $0.60. The valuation reflects a sum of parts based on the NPV of Analytical Services unit, the NPV of the licence agreement for the distribution of PromarkerD in the Dominican Republic, and a risk adjusted value of PromakerD in the US and China.
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Independent Investment Research, “IIR”, is an independent investment research house based in Australia and the United States. IIR specialises in independent research in small/ micro cap equities across sectors and managed investment ratings both listed and unlisted. The research is for Financial Planners, Brokers, Family Offices and Fund Managers. IIR distributes its research in Asia, United States and Europe. Importantly, IIR does not participate in any corporate or capital raising activity or advice and therefore it does not have any inherent bias that may result from research that is linked to any corporate/ capital raising activity. Analyst remuneration is not linked to stock/ fund performance, in fact the remuneration does not have any nexus to company/ fund pricing, performance or like. Analyst are prohibited to participate in any promotional activity that may compromise the independent of its research.
IIR was established in 2004 under Aegis Equities Research Group of companies to provide investment research to a select group of retail and wholesale clients. Since March 2010, IIR (the Aegis Equities business was sold to Morningstar) has operated independently from Aegis by former Aegis senior executives/shareholders to provide clients with unparalleled research that covers listed and unlisted managed investments, listed companies, structured products, and IPOs.
IIR takes great pride in the quality and independence of our analysis, underpinned by high caliber staff and a transparent, proven and rigorous research methodology.
Independent Investment Research
Independent Investment Research
Independent Investment Research, “IIR”, is an independent investment research house based in Australia and the United States. IIR specialises in independent research in small/ micro cap equities across sectors and managed investment ratings both...
Expertise
Independent Investment Research
Independent Investment Research
Independent Investment Research, “IIR”, is an independent investment research house based in Australia and the United States. IIR specialises in independent research in small/ micro cap equities across sectors and managed investment ratings both...
Expertise
Comments
Comments
Sign In or Join Free to comment